MAGNETIC RESONANCE IMAGING
NVision Imaging is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
One of the key issues in today's cancer therapy
THERE ARE MORE THERAPY OPTIONS THAN TIME TO TRY THEM.
METABOLIC MRI PROVIDES UNPRECEDENTED INSIGHTS AT CELLULAR LEVEL.
Detects slow-changing effects at tissue level.
Detects early changes of key metabolic pathways at cellular level.
NVISION'S INSIGHTS AT CELLULAR LEVEL ALLOW EARLIEST ASSESSMENT OF RESPONSE TO CANCER THERAPY.
Changes at tissue level:
Typically, changes are visible only months after onset of treatment.
Changes at cellular level:
Effective treatment induces metabolic response in tumor cells within days, visible with Metabolic MRI.
METABOLIC MRI FOR ADAPTIVE CANCER TREATMENT
Differentiation between resistant and sensitive tumors within days by means of Metabolic MRI: Patients who are found to have resistant tumors can shift to a combination therapy or alternate drug, whereas patients who are found to have sensitive tumors can confidently continue with the sametreatment - but with certainty.
~ 7 days
RESISTANT / SENSITIVE
Metabolic MRI ushers in a new era
A NEW ERA OF ADAPTIVE CANCER TREATMENT, BASED ON EARLIEST ASSESSMENT OF METABOLIC RESPONSE
HIGH IMPACT ACROSS MANY MEDICAL FIELDS - IN ONCOLOGY AND BEYOND
Treatment response assessment, early diagnosis and non-invasive assessment of tumor aggressiveness.
> current focus <
Improved diagnosis and guidance of intervention in ischemic heart disease, and monitoring treatment response in heart failure patients.
Early diagnosis and treatment response assessment for nonalcoholic steatohepatitis (NASH).
Assessment of etiology and treatment response in chronic and acute kidney failure.
Early diagnosis and treatment response assessment over a wide range of neurodegenerative, inflammatory, ischemic, and traumatic conditions.
Early diagnosis and treatment response assessment for inflammatory arthritis and other inflammatory conditions.
Sella Brosh, M.D.
Chief Executive Officer
Ilai Schwartz M.Sc.
Co-Founder & CTO
Prof. Martin Plenio
Prof. Fedor Jelezko
Prof. Alex Retzker
NVision is funded by deep-tech investors and highly-competitive grants,
collaborating with top-tier medical and research units in US and EU
Playground is a VC firm that partners with entrepreneurs working at the intersection of atoms, bits, and AI to build the companies of tomorrow.
b-to-v is a European VC and investor network focused on investments in deep-technology companies.
Entree Capital is a team of former serial founders managing $1B across a number of funds, with offices in Tel Aviv, London, and New York.
Lauder Partners is an investor in various realms of the technology field and in radical innovations.
ES Kapital is a European VC and investor network focused on investments in deep-technology companies.